Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Double-blind, Placebo-controlled, Parallel-group, Phase IV Study to Assess the Effect of Rotigotine on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease

NCT01300819 is registered in ClinicalTrials.gov with UCB Pharma as lead sponsor.

NCT NCT01300819
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01300819 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Double-blind, Placebo-controlled, Parallel-group, Phase IV Study to Assess the Effect of Rotigotine on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease
Lead sponsor
UCB Pharma
Phase
Phase 4
Overall status
Completed
Start date
February 28, 2011
Completion date
November 30, 2012
Enrollment
349 (actual)
Sites
87

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic parkinson's disease